In:
Head & Neck, Wiley, Vol. 45, No. 5 ( 2023-05), p. 1281-1287
Abstract:
We sought to characterize early changes in CD8 + tumor‐infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16‐positive oropharyngeal cancer on a phase II clinical de‐escalation trial. Methods Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8 + tumor‐infiltrating lymphocytes and transcriptomes were assessed. Results One week after cetuximab, five patients (62.5%) had an increase in CD8 + cell infiltration with a median (range) fold change of +5.8 (2.5–15.8). Three (37.5%) had unchanged CD8 + cells (median [range] fold change of −0.85 [0.8–1.1] ). In two patients with evaluable RNA, cetuximab induced rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways. Conclusions Within 1 week, cetuximab induced measurable changes in pro‐cytotoxic T‐cell signaling and immune content.
Type of Medium:
Online Resource
ISSN:
1043-3074
,
1097-0347
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2001440-5